Pathbreaking treatment
for rare diseases

Latest news

January 12, 2026 Advicenne has successfully renewed the Marketing Authorization of Sibnayal® in European Union

November 4, 2025 Advicenne has submitted to the US FDA the registration application (NDA) for Sibnayal® in dRTA treatment

September 19, 2025 Advicenne reports First Half financial results as of June 30, 2025, and updates on its activities

August 26, 2025 Advicenne announces the publication in Orphanet Journal of Rare Diseases of the long-term European study results of dRTA treatment using ADV7103

July 28, 2025 Advicenne receives marketing authorization and reimbursement for Sibnayal® in Saudi Arabia

July 25, 2025 Advicenne reports its H1 2025 sales

July 21, 2025 Advicenne raises 2.6 million euros in its capital increase and extends its financial visibility

April 29, 2025 Advicenne 2024 Universal Registration Document made available

March 27, 2025 Advicenne: Fiscal year 2024 marked by the satisfactory commercial performance of Sibnayal® in Europe and development in the United States

January 29, 2025 Advicenne reaches a significant milestone with the US FDA in the development of ADV7103 in cystinuria

January 23, 2025 Advicenne announces 2024 gross sales

December 19, 2024 Advicenne finalizes agreement with Primex Pharmaceuticals AG

November 28, 2024 Advicenne announces its 2025 financial calendar

October 1, 2024 Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103

September 18, 2024 Advicenne reports its First Half financial results as of June 30, 2024, and updates on its activities

July 18, 2024 Advicenne announces an 8.8% increase in gross sales for H1 2024 and provides an update on its activities

May 15, 2024 Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

April 5, 2024 Advicenne 2023 Universal Registration Document made available

March 28, 2024 Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal®

March 25, 2024 FDA grants Orphan Drug Designation to ADV7103 for the treatment of cystinuria

January 23, 2024 Advicenne reports 2023 gross sales up 20% to €4.43 million

December 28, 2023 Advicenne announces its 2024 financial calendar

October 2, 2023 Advicenne announces the results of its capital increase with preferential subscription rights

September 25, 2023 Advicenne announces its participation in several scientific conferences and the presentation of updated clinical results about ADV7103

September 11, 2023 Advicenne reports its First Half Financial results as of June 30, 2023 and updates on its activities

July 12, 2023 Advicenne announces 51% growth in Sibnayal® gross sales in H1 2023 to almost €1.0 million

June 14, 2023 Advicenne announces long-term results of the European clinical development program for ADV7103

June 9, 2023 Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

May 19, 2023 Advicenne annual combined general meeting of June 8, 2023 – Availability of preparatory documents

April 28, 2023 Advicenne 2022 Universal Registration Document made available

March 30, 2023 Advicenne reports its financial results for the year ended December 31, 2022

March 6, 2023 Advicenne announces the launch of Sibnayal® in Denmark

February 28, 2023 Advicenne completes European commercial coverage of Sibnayal® through its agreement with Avanzanite Bioscience

February 14, 2023 Advicenne and SPA announce an exclusive distribution agreement for the marketing of Sibnayal® in Italy, Spain and Portugal

February 1, 2023 Advicenne provides an update on its commercial partnerships in Europe and the Middle East

January 24, 2023 Advicenne reports 2022 sales up 13% to €3.7 million

December 13, 2022 Advicenne obtains Orphan Drug Designation for ADV7103 in the United States for the treatment of distal Renal Tubular Acidosis (dRTA)

December 5, 2022 Advicenne announces the second tranche drawdown of its non-dilutive financing agreement with the EIB

November 30, 2022 Advicenne announces its financial calendar for 2023

November 3, 2022 Advicenne announces its upcoming participation in two of the most important international investor conferences

October 5, 2022 Advicenne announces the extension of the intellectual property of its drug Sibnayal®

September 21, 2022 Advicenne reports its First Half Financial results as of June 30, 2022

September 14, 2022 Advicenne updates on availability of Sibnayal® to patients and caregivers in Great Britain

June 30, 2022 Advicenne announces commercial launch of Sibnayal® in Great Britain

June 28, 2022 Advicenne announces commercialization agreement with Taïba Healthcare for Sibnayal® in Middle-East

June 10, 2022 Advicenne provides an update on its activities following its Annual General Meeting and Board of Directors meeting on June 9, 2022

May 30, 2022 Advicenne announces the launch of its new website

April 29, 2022 Advicenne 2021 Universal Registration Document made available

April 21, 2022 Advicenne appoints Philippe Boucheron as Chairman of its Board of Directors

April 5, 2022 A case report highlights the interest of a long-term treatment with ADV-7103 in dRTA

March 31, 2022 Advicenne Reports its Financial Results for the Year ended 31 December 2021

March 30, 2022 Advicenne announces the release of results of a study showing improved quality of life in patients living with DRTa and treated by ADV7103

March 28, 2022 Advicenne announces the transfer of its shares from Euronext Paris and Euronext Brussels to Euronext Growth Paris on March 30, 2022

January 21, 2022 Advicenne ordinary shareholders’ meeting approved the project to transfer Advicenne’s shares listing to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels

January 18, 2022 Advicenne reports 2021 sales up 20% to €3.3 million

January 4, 2022 Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region

December 27, 2021 Advicenne announces its financial calendar for 2022

December 20, 2021 Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug Sibnayal™ in dRTA

December 7, 2021 Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe

December 3, 2021 Proposed transfer of the listing of Advicenne’s shares to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels

September 29, 2021 Advicenne Reports 2021 Half Year Financial Results

July 2, 2021 Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

June 23, 2021 Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons

June 22, 2021 Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m

June 15, 2021 Advicenne provides an update on its activities following its Annual General Meeting

June 10, 2021 Live Broadcast of the Annual General Meeting on June 14th, at 11:00 a.m

May 17, 2021 Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)

May 3, 2021 Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation

April 28, 2021 Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook

April 23, 2021 2021 Financial Calendar

March 25, 2021 Precision on the press release dated March 19, 2021

March 19, 2021 Advicenne expects imminent marketing authorization for ADV7103 (Sibnayal™) for dRTA in Europe

February 18, 2021 Advicenne Provides an Update as its Operations Evolve

January 7, 2021 Advicenne Announces the Appointment of Peter Meeus as Chief Executive Officer

December 10, 2020 Advicenne receives positive CHMP opinion recommending approval of ADV7103 (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)

October 27, 2020 Advicenne obtains non-dilutive loan facility of €4.3 million guaranteed by the French State

September 25, 2020 Advicenne Presents 2020 Half-Year Financial Report and Provides Update on Outlook and Recent Developments

August 11, 2020 Advicenne Strengthens Its Financial Structure Through the Implementation of its €20 Million Financing Agreement with the European Investment Bank, with the Drawdown of a First Tranche of €7.5 Million

May 26, 2020 Advicenne Shareholders Adopt All Resolutions Recommended by the Board of Directors at Its Combined Shareholders Meeting

May 25, 2020 Advicenne Gears Up for Accelerated Growth

May 5, 2020 Advicenne Combined Shareholders Meeting to Be Held on May 26 Behind Closed Doors

March 13, 2020 Advicenne Reports Full-Year 2019 Financial Results and Confirms Operational Outlook for 2020

March 13, 2020 Advicenne Announces the Appointment of André Ulmann as Interim Chief Executive Officer

March 10, 2020 Advicenne Makes ADV7103 8 mEq and 24 mEq Prolonged-Release Granules Available Within Framework of French Temporary Authorization for Use (TAU) Scheme

January 28, 2020 Advicenne Publishes its Financial Calendar for 2020

December 18, 2019 Advicenne’s Lead Candidate Approved for Orphan Drug Designation in the Treatment of Cystinuria in Europe

November 15, 2019 Advicenne intends to appoint David Horn Solomon as Chairman of the Board of Directors in line with its International Strategy

October 28, 2019 Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress

September 27, 2019 Advicenne Publishes its 2019 Half-Year Financial Report

September 24, 2019 Advicenne Presents 2019 Half-Year Financial Report and Confirms Financial Outlook

September 20, 2019 Advicenne to present eight posters on the positive results of ADV7103 in the treatment of rare nephrological diseases at major international conferences

September 4, 2019 Advicenne secures production of ADV7103 through long-term manufacturing supply agreement with Elaiapharm Lundbeck

September 3, 2019 Advicenne to attend the J.P. Morgan Pan European Small / Mid Cap Conference in London

August 29, 2019 Advicenne Announces First Patient Enrolled in US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 in distal Renal Tubular Acidosis (dRTA)

July 26, 2019 Advicenne to Present at the Solebury Trout European Biotech Investor Day in NYC

July 18, 2019 Financial Visibility and Accelerated Development

June 13, 2019 Advicenne confirms prevalence of distal renal tubular acidosis (dRTA) and cystinuria at ISPOR conference

June 12, 2019 Advicenne announces the successful listing of its shares on the regulated market of Euronext Brussels

May 23, 2019 Advicenne announces its intention to list on the regulated market of Euronext Brussels

April 30, 2019 Advicenne Publishes its 2018 Annual Financial Report

April 9, 2019 Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris

March 21, 2019 Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

March 12, 2019 Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)

January 7, 2019 Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium

December 21, 2018 Advicenne Publishes its Financial Calendar for 2019

October 26, 2018 Advicenne Wins Prestigious Prix Galien – Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes

October 15, 2018 Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

October 4, 2018 Advicenne to present additional data on ADV7103 at the European Society for Paediatric Nephrology during its 51st Annual Meeting

September 25, 2018 Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

September 20, 2018 Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018

September 12, 2018 Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

September 5, 2018 Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

July 2, 2018 Advicenne confirms ADV7103’ safety and efficacy after 24 months in the Phase III Extension Study

May 31, 2018 Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

May 15, 2018 Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

May 4, 2018 Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria

April 30, 2018 Advicenne publishes its annual financial report

April 18, 2018 Advicenne 2017 Financial Results and Operational Perspectives for 2018

February 12, 2018 Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017

January 24, 2018 Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs

January 5, 2018 Partial exercise of over – allotment option

December 5, 2017 Success of the IPO

November 21, 2017 Advicenne launches IPO on Euronext’s regulated market in Paris

November 6, 2017 ADV7103: 6-month data presented at ASN

November 2, 2017 Advicenne announces the registration of its Document De Base in relation to its planned IPO on Euronext’s regulated market in Paris

September 20, 2017 Advicenne to Present a Poster at the 9th EuPFI Conference on ADV7103, an Innovative age-adapted Product for distal Renal Tubular Acidosis

September 11, 2017 Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis

July 2, 2017 Advicenne Receives Orphan Drug Designation from the EU for ADV7103 for the Treatment of distal Renal Tubulopathy

June 21, 2017 Advicenne to Present Preliminary Phase III Clinical Data on ADV7103 at the Upcoming European Society of Paediatric Nephrology’s Annual Meeting

March 20, 2017 Advicenne Announces the Closing of a €16 Million Financing Round

September 1, 2016 Advicenne appoints Ludovic Robin as Chief Business & Strategy Officer

February 23, 2016 Advicenne Pharma sells its drug candidate ADV6209 for moderate sedation to the Swiss Primex Pharmaceuticals

April 23, 2015 French marketing authorization approval for Levidcen

February 20, 2014 Advicenne has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules

+ View all news

Our Focus

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases.

Our Products

Advicenne have spent more than 10 years developing products for the treatment of rare renal diseases. Click the link below to learn more about our products.

Sibnayal

Our Commitment

At Advicenne, we are committed to developing and commercializing medicines that are suitable for both children and adults – groundbreaking treatments for rare diseases should be available to patients of all ages.